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292a Monday, February 9, 2015decreased in AB cardiomyocytes with increasing pacing frequency, re-
vealing a negative shortening-frequency relationship that was attenuated
by both drug treatments. Length:width ratio was decreased in AB and
AB-TAD animals with commensurate decreases in left ventricular (LV)
end diastolic and end systolic volumes. Normal cardiomyocyte size and
LV volumes were preserved in the AB-SAX group. Interestingly, all AB
groups exhibited similar gross hypertrophic remodeling (heart weight:body
weight ratio) despite differences in cardiomyocyte morphology. In conclu-
sion, saxagliptin appears superior for preserving normal cardiomyocyte
morphology and overall function versus tadalafil, independent of changes
in cGMP-PKG activity.
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Quercetin (3, 30, 40, 5, 7-pentahydroxyflavone, QCT) is a major flavonoid of
plants, known to exhibit anti-oxidative, anti-inflammatory, and anti-cancer
effects. QCT has been demonstrated to have a cardioprotective effect
through its antioxidant activity. In the present study, we found that QCT
markedly enhanced the contractility of a single cardiomyocyte isolated
from mouse hearts in a dynamic fashion even under conditions with no
apparent oxidative stress. Simultaneous measurement of Ca2þ transient in
a Fura-2 loaded single cardiomyocyte revealed that QCT markedly increased
the cytoplasmic Ca2þ both at diastole and systole under regular electrical
stimulation. Echocardiography revealed that intravenous administration of
QCT also increased the left ventricular systolic function of the heart evalu-
ated by ejection fraction in mice with reduced cardiac function due to a mu-
tation causing genetic dilated cardiomyopathy (delK210 mutation in cardiac
troponin T). QCT did not change the maximum force-generating capability
and Ca2þ sensitivity of force generation in skinned (membrane-permeabi-
lized) cardiac muscle fibers prepared from mouse hearts, indicating that
QCT has no direct effects on the contractile machinery in cardiomyocytes.
These findings indicates that QCT has a direct cardiotonic effect through
enhancing the Ca2þ transient in cardiomyocytes independently of its anti-
oxidative action. Studies on the molecular mechanisms underlying these phe-
nomena are in progress.
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We examined the relationships between troponin I phosphorylation and Ca2þ-
regulation of contractility in single myofibrils from a mouse model of famil-
ial DCM (ACTC E361G) in comparison with non-transgenic (NTG) . We
measured the effects of changing [Ca2þ] and troponin I phosphorylation level
on myofibril contractility. Propranolol treatment of mice was used to reduce the
level of troponin I in their hearts prior to isolating the myofibrils.
For non-transgenic mouse myofibrils we found that when the TnI phosphoryla-
tion level was reduced from 1.02 to 0.3 the Ca2þ-sensitivity of force was
increased (EC50P/unP¼1.8), relaxation parameter kREL was reduced and tLIN
was increased. ACTCE361G mouse myofibrils were uncoupled: Ca2þ-sensi-
tivity and relaxation parameters did not depend on troponin I phosphorylation
level (EC50P/unP¼0.88). Nevertheless, modulation of Ca2þ-sensitivity by
sarcomere length or due to EMD57033 was retained.
The Ca2þ-desensitiser Epigallocatechin-3-gallate (EGCG) decreased Ca2þ-
sensitivity in phosphorylated and unphosphorylated NTG myofibrils equally
(EC50 P/uP¼ 0.5050.06 and 0.4550.07 respectively) but did not change
the relaxation parameters tLIN and kRE. The rate of force development
(kACT), measured at high Ca
2þ, was unchanged in myofibrils with phosphory-
lated TnI and 22% decreased in unphosphorylated myofibrils indicating that
EGCG affects cross-bridge activation kinetics.
EGCG reduced Ca2þ-sensitivity and kACT in both phosphorylated and unphos-
phorylated ACTCE361G myofibrils. The change in EC50 was more in phos-
phorylated than unphosphorylated myofibrils, consequently EGCG restored
the lost difference in EC50 values between phosphorylated and unphosphory-
lated myofibrils and also the difference in relaxation parameters tLIN and
kREL. The observation that EGCG does not affect either the EC50 P/ EC50unP or tLIN in NTG myofibrils but changes them in ACTG E361G suggests
that EGCG can restore modulation of cardiac contractile function by TnI phos-
phorylation to DCM mutant myofibrils independently of its Ca2þ-desensitising
function.
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Whole exon sequence data from 28 FDCM patient cardiac muscle samples was
screened for potentially disease-causing mutations in 58 genes previously
implicated in HCM or DCM . We identified OBSCN gene mutations in 5 sam-
ples; one sample had two OBSCN mutations, one also had a DSP mutation and
another also had a SCN5A mutation Also identified were 6 truncating muta-
tions in TTN, 3 mutations in MYH7, 2 in DSP and one each in TNNC1,
TNNI3, MYOM1, VCL, GLA, PLB, PKP2 and LAMA4 .
The mean level of obscurin mRNA was significantly greater and more variable
in donor samples than the FDCM samples (1.6950.53, n¼58 compared with
0.5750.10,n¼ 68, p¼0.0025). The mRNA content of FDCM samples was
not significantly different with and without OBSCN mutations.
The obscurin protein band was estimated to be <1% of the abundance of
titin; it was identified and quantified with antibodies. The apparent mass
was 9605 60 kDa. The OBSCN mutation samples had levels of expres-
sion, significantly different from FDCM samples without obscurin muta-
tions, donor hearts or myectomies. Four OBSCN mutant samples exhibited
low levels of obscurin protein (48, 61, 51,and 70% of the level in control
FDCM samples). One OBSCN mutant sample exhibited 34% more
expression.
Immunofluorescence microscopy using obscurin, myomesin and a-actinin-spe-
cific antibodies showed that obscurin was located at the level of the M-line and
preferentially labelled the sides of the myofibrils. There was no apparent differ-
ences between wild-type and mutant samples.
Mutations in the obscurin gene should be considered as a significant cause
of FDCM, alone or in concert with another mutation. Disease-related OBSCN
mutations cause demonstrably abnormal expression in myofibrils that could
account for the development of a DCM phenotype.
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Thyroid hormones are key regulators of basal metabolic state and oxidative
metabolism. Hyperthyroidism has been reported to cause significant alter-
ations in hemodynamics, and cardiac and diaphragm muscle function,
all which have been linked to increased oxidative stress. Previously, we
have shown that thyroxin (T4) treatment in mice resulted in hypertension,
increased cardiac reactive oxygen species (ROS), cardiac hypertrophy,
and cardiac contractile dysfunction. Here, we sought to investigate the
functional impact of T4 on diaphragm muscle function as well as to iden-
tify the role and the source(s) of ROS in these distinct phenotypes of
our model. Wild-type and T4 mice with and without 2-week treatments
with allopurinol (xanthine oxidase inhibitor), apocynin (NADPH-oxidase
inhibitor), L-NIO (nitric oxide synthase inhibitor), or MitoTEMPO (mito-
chondria-targeted antioxidant) were studied. Blood pressure and echocardi-
ography were non-invasively evaluated, followed by ex-vivo assessments
of isolated heart and diaphragm muscle functions. Treatment with L-NIO
attenuated the T4-induced hypertension in mice. However, apocynin im-
proved the left ventricular (LV) dysfunction without preventing the cardiac
hypertrophy in these mice. Both allopurinol and MitoTEMPO reduced the
T4-induced fatigability of the diaphragm muscles. In conclusion, we show
here for the first time that T4 exerts differential effects on various sources
of ROS to induce distinct cardiovascular and skeletal muscle phenotypes.
Additionally, we find that T4-induced LV dysfunction is independent
of cardiac hypertrophy, while NADPH-oxidase is a key player in this pro-
cess. Furthermore, we prove the significance of both xanthine-oxidase
and mitochondrial ROS pathways in T4-induced fatigability of diaphragm
muscles.
